On the afternoon of April 6, 2022, the 4th Asian Network Meeting was held online. Heads of national medical products regulatory authorities of China, India, Indonesia, Japan, the Republic of Korea, Malaysia, Myanmar, the Philippines, Singapore, Vietnam and Thailand exchanged views on regulatory cooperation against the pandemic in Asia, construction of a pharmaceutical ecosystem in Asia, and improvement of the accessibility and affordability of medicines. Xu Jinghe, Vice Commissioner of the China NMPA, attended the meeting and delivered a speech.

Mr. Xu said that the Asian Network Meeting provides an important communication platform for medical products regulatory authorities in Asia to continuously focus on regulatory issues with common characteristics of the Asian region and facilitate the development of medical products regulatory capacity in Asia with a broad vision. In recent years, medical products regulatory authorities in China have been adhering to the people-centered philosophy of development, adhering to the lofty mission of protecting and promoting public health, adhering to the scientific, legalized, international and modernized development path, continuously deepening the reform of drug and medical device review and approval system, continuously advancing the development and marketing as well as quality supervision of drugs and medical device products for pandemic prevention and control, continuously carrying out medical products regulatory scientific research, and continuously enhancing the construction of the medical products regulatory system and regulatory capacity, and the medical products regulatory reform and innovation has embarked on a new journey, creating a new situation. We look forward to further deepening exchanges and cooperation between regulatory authorities in Asian countries, jointly enhancing regulatory capacity and level, and making new contributions to global health.

Persons in charge of the Department of Science, Technology and International Cooperation, Department of Drug Registration, Department of Drug Regulation, Center for Drug Evaluation, and Center for Food and Drug Inspection participated in the meeting.